Nephrotoxicity, as evidenced by renal insufficiency is a well-known consequence of gentamicin therapy. We report two patients with gentamicin-induced syndrome of hypokalemic metabolic alkalosis and hypomagnesemia. Both had complete recovery of renal tubular function after cessation of antibiotic therapy. These cases emphasize the need to routinely monitor patients receiving gentamicin therapy for electrolyte abnormalities to avoid potential morbidity.
Get full access to this article
View all access options for this article.
References
1.
1. Bartter FC, Ponove P, Gill JR, MacCardle RC. Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. AmJMed. 1962;33:811-828.
2.
2. Gill JR, Bartter FC. Evidence for a prostaglandin independent defect in chloride reabsorption in loop of Henle as a proximal cause of Bartter's syndrome. AmJMed. 1978;65:765-772.
3.
3. Simon DB, Karet FE, Hamdam JM, et al. Bartter's syndrome, hypokalemic metabolic alkalosis, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nature Genet. 1996;13:183-188.
4.
4. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter syndrome, inherited hypokalemic metabolic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nature Genet. 1996;12:24-30.
5.
5. International Collaborative Study Group for Bartter-like Syndromes. Mutations encoding the inwardly rectifying renal potassium channel, ROMK, cause antenatal variant of Bartter syndrome: evidence for genetic heterogeneity. Hum Mol Genet. 1997;6:17-26.
6.
6. Jamison RL, Ross JC, Kempson M, et al. Surreptitious diuretic ingestion and pseudo-Bartter's syndrome. AmJ Med. 1982;73:142-147.
7.
7. Sasaki S, Okumura M, Kawasaki T, et al. Indomethacin and atrial natriuretic peptide in pseudo-Bartter's syndrome. NEnglJMed. 1987;316:167-167.
8.
8. Gill JR. Bartter's syndrome. Annu Rev Med. 1980;31:405-419.
9.
9. Holmes AM, Hesling CM, Wilson TM. Drug-induced secondary hyperaldosteronism in patients with pulmonary tuberculosis. QJ Med. 1970;39:229-315.
10.
10. Bar RS, Wilson HE, Mazzaferi EL. Hypomagnesemic hypocalcemia secondary to renal magnesium wasting. A possible consequence of high-dose gentamicin therapy. Ann Intern Med. 1975;82:646-649.
11.
11. Patel R, Savage A. Symptomatic hypomagnesemia associated with gentamicin therapy. Nephron. 1979;23:50-52.
12.
12. Finton CK, Blorkland S, Zaloga GP, et al. Gentamicin-induced hypomagnesemia. Am Surg. 1983;49:576-578.
13.
13. Steiner RW, Omachi AS. A Bartter-like syndrome from capreomycin, and a similar gentamicin tubulopathy. AmJ Kidney Dis. 1986;7:245-249.
14.
14. Kes P, Reiner Z. Symptomatic hypomagnesemia associated with gentamicin therapy. Magnes Trace Elem. 1990;9:54-60.
15.
15. Tezic T, Saraclar Y, Bilginturan, Kilcioglu I. Symptomatic hypocalcemia and hypomagnesemia due to gentamicin therapy in an 8-year-old girl. Turk J Pediatr1982;24:267-269.
16.
16. Kelnar CJH, Tao WS, Reynolds DJ, et al. Hypomagnesemic hypocalcemia with hypokalemia caused by treatment with high-dose gentamicin. Arch Dis Child. 1978;53:817-820.
18. Milman N. Renal failure associated with gentamicin therapy. Acta Med Scand. 1974;196:87-91.
19.
19. Humes HD, Weinberg JM, Knauss TC. Clinical and pathophysiological aspects of aminoglycoside nephrotoxicity. AmJKidney Dis. 1982;2:5-29.
20.
20. Smith CR, Baughman KL, Edwards CQ et al. Controlled comparison of amikacin and gentamicin. N EnglJ Med. 1977;296:349-355.
21.
21. Bennett WM, Plamp CE, Gilbert DN, et al. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure.JInfect Dis. 1979;140:576-579.
22.
22. Smith CR, LipskyJ, Laskin O, et al. Double-blind comparison of nephrotoxicity and auditory toxicity of gentamicin and tobramycin. NFnglJMed. 1980;302:1106-1109.
23.
23. Smith CR, Moore RD, Lietman PS. Studies of risk factors for aminoglycoside nephrotoxicity. Am J Kidney Dis. 1986;8:308-313.
24.
24. Brinker KR, Bulger RE, Dobyan DC, et al. Effect of potassium depletion on gentamicin nephrotoxicity. JLab ClinMed. 1981;98:292-301.
25.
25. Klotman PE, Boatman JE, Volpp BD, et al. Captopril enhances aminoglycoside nephrotoxicity in potassium-depleted rats. Kidney Int. 1985; 28:118-127.
26.
26. Seguro AC, Massola-Shimuzu MA, Monteiro JL, Santos Roch A. Effect of potassium depletion on ischemic renal failure. Nephron. 1989;51:350-354.
27.
27. Kourilsky O, Solez K, Morel-Maroger L, et al. The pathology of acute renal failure due to interstitial nephritis in man with comments on the role of interstitial inflammation and sex in gentamicin nephrotoxicity. Medicine (Baltimore). 1982;61:258-268.
28.
28. Horton P, Biglieri EG. Effect of aldosterone on the metabolism of magnesium. J Clin Endocrinol Metab. 1962; 22:1187-1192.
29.
29. Howard K, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Med. 1996;2:467-469.
30.
30. Parsons PP, Garland HO, Harpur ES, Old S. Acute gentamicin-induced hypercalciuria and hypermagnesiuria in the rat: dose-response relationship and role of renal tubular injury. BrJ Pharmacol. 1997;122:570-576.
